Novo Nordisk A/S - NVO Stock Forecast, Price & News

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NVO shares.
View NVO analyst ratings or view top-rated stocks.

16 brokerages have issued 1-year price targets for Novo Nordisk A/S's shares. Their NVO share price forecasts range from $145.00 to $1,100.00. On average, they anticipate the company's stock price to reach $697.78 in the next twelve months. This suggests a possible upside of 401.8% from the stock's current price.
View analysts price targets for NVO or view top-rated stocks among Wall Street analysts.

Novo Nordisk A/S's stock was trading at $135.34 on January 1st, 2023. Since then, NVO shares have increased by 2.7% and is now trading at $139.06.
View the best growth stocks for 2023 here.

Novo Nordisk A/S saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 1,840,000 shares, an increase of 34.3% from the December 15th total of 1,370,000 shares. Based on an average daily volume of 1,330,000 shares, the days-to-cover ratio is presently 1.4 days. Approximately 0.1% of the shares of the company are short sold.
View Novo Nordisk A/S's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 1st 2023.
View our NVO earnings forecast.

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings results on Wednesday, November, 2nd. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.84 by $0.02. The company had revenue of $6.17 billion for the quarter, compared to analysts' expectations of $6.09 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 72.57% and a net margin of 31.57%.

Novo Nordisk A/S announced a semi-annual dividend on Friday, August 5th. Shareholders of record on Monday, August 15th will be given a dividend of $0.5836 per share on Tuesday, August 23rd. This represents a yield of 1.1%. The ex-dividend date of this dividend is Friday, August 12th.
Read our dividend analysis for NVO.

Novo Nordisk A/S (NYSE:NVO) pays an annual dividend of $0.81 per share and currently has a dividend yield of 0.59%. The dividend payout ratio is 24.04%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVO will have a dividend payout ratio of 19.38% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVO.

Novo Nordisk A/S issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $23.66 billion-$24.23 billion, compared to the consensus revenue estimate of $22.97 billion.

372 employees have rated Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among the company's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S's stock is owned by a number of institutional and retail investors. Top institutional investors include Everett Harris & Co. CA (0.15%), Natixis Advisors L.P. (0.06%), DAVENPORT & Co LLC (0.02%), Calamos Advisors LLC (0.01%), Beacon Investment Advisory Services Inc. (0.01%) and Vantage Investment Partners LLC (0.01%).
View institutional ownership trends.

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVO stock can currently be purchased for approximately $139.06.

Novo Nordisk A/S (NYSE:NVO) has a market capitalization of $314.69 billion and generates $22.40 billion in revenue each year. The company earns $7.60 billion in net income (profit) each year or $3.37 on an earnings per share basis.

The company employs 45,000 workers across the globe.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The official website for the company is www.novonordisk.com. The company can be reached via phone at (454) 444-8888, via email at phak@novonordisk.com, or via fax at 45-4449-0555.